Research
Dr. Mathews’ research program seeks to understand how neural communication between brain regions, in particular the cerebellum and forebrain gives rise to complex animal behavior. His current research goals are to (1) define region-specific connectivity between the cerebellum and forebrain, (2) elucidate the neural influence the cerebellum has on downstream forebrain structures (e.g. basal ganglia and prefrontal cortex), and (3) to elucidate the neural information provided by the cerebellum to the forebrain in non-motor behaviors (e.g. reversal learning).
The Mathews Lab currently incorporates a multifaceted set of approaches to answer these questions including in vivo multi-electrode recordings, functional Magnetic Resonance Imaging (fMRI), function Ulrasound (fUS), and animal behavioral testing and anatomy. Furthermore, they are complementing these approaches with both directed (e.g. DREADD or optogenetic manipulation) and/or disease related (e.g. mouse models of autism) disruptions in cerebellar-forebrain communication to significantly advance our understanding of cerebellar-forebrain communication and its role in non-motor behavior.
A second major component of Dr. Mathews’ research program is to understand and devise potential treatments for the disease Ataxia-Telangiectasia (A-T). To do so, his lab recently created a new mouse model of A-T that for the first time displays the phenotypical loss of motor control and contains a human related genetic mutation (i.e. nonsense mutation). With this new model they are elucidating the neuropathogenesis of the disease and testing a new small molecule therapeutic designed to read-through premature termination codons.
In collaboration with others at The Lundquist Institute, his team are further testing and developing the therapeutic potential of these small molecule read-through (SMRT) compounds along with combinatorial approaches to restore protein production in an array diseases caused by a premature stop codons.
Biography
Publications
Perez H, Abdallah MF, Chavira JI, Norris AS, Egeland MT, Vo KL, Buechsenschuetz CL, Sanghez V, Kim JL, Pind M, Nakamura K, Hicks GG, Gatti RA, Madrenas J, Iacovino M, McKinnon PJ, Mathews PJ. A novel, ataxic mouse model of ataxia telangiectasia caused by a clinically relevant nonsense mutation. Elife. 2021 Nov 1;10. doi: 10.7554/eLife.64695. PubMed PMID: 34723800; PubMed Central PMCID: PMC8601662.
Choe KY, Sanchez CF, Harris NG, Otis TS, Mathews PJ. Optogenetic fMRI and electrophysiological identification of region-specific connectivity between the cerebellar cortex and forebrain. Neuroimage. 2018 Jun;173:370-383. doi: 10.1016/j.neuroimage.2018.02.047. Epub 2018 Feb 27. PubMed PMID: 29496611; PubMed Central PMCID: PMC5911204.
Ekins S, Mathews P, Saito EK, Diaz N, Naylor D, Chung J, McMurtray AM. α7-Nicotinic acetylcholine receptor inhibition by indinavir: implications for cognitive dysfunction in treated HIV disease. AIDS. 2017 May 15;31(8):1083-1089. doi: 10.1097/QAD.0000000000001488. PubMed PMID: 28358738.
Ekins S, Diaz N, Chung J, Mathews P, McMurtray A. Enabling Anyone to Translate Clinically Relevant Ideas to Therapies.Pharm Res. 2017 Jan;34(1):1-6. doi: 10.1007/s11095-016-2039-5. Epub 2016 Sep 12. PubMed PMID: 27620174.
Lee KH, Mathews PJ, Reeves AM, Choe KY, Jami SA, Serrano RE, Otis TS. Circuit mechanisms underlying motor memory formation in the cerebellum. Neuron. 2015 Apr 22;86(2):529-40. doi: 10.1016/j.neuron.2015.03.010. Epub 2015 Apr 2. PubMed PMID: 25843404; PubMed Central PMCID: PMC4417109.
Mathews PJ, Lee KH, Peng Z, Houser CR, Otis TS. Effects of climbing fiber driven inhibition on Purkinje neuron spiking. J Neurosci. 2012 Dec 12;32(50):17988-97. doi: 10.1523/JNEUROSCI.3916-12.2012. PubMed PMID: 23238715; PubMed Central PMCID: PMC3532857.
Otis TS, Mathews PJ, Lee KH, Maiz J. How do climbing fibers teach?. Front Neural Circuits. 2012;6:95. doi: 10.3389/fncir.2012.00095. eCollection 2012. PubMed PMID: 23226116; PubMed Central PMCID: PMC3510640.